Manufacturing challenges: Semaglutide is a peptide-based drug, requiring complex synthesis and sterile production, which limits who can make it at scale
No published data exist examining its pharmacokinetic or pharmacodynamic interactions with any other peptide, meaning the potential for additive side effects, unexpected hormonal disruption, or dangerous interactions is entirely unknown
The LIVE trial, conducted in stable HFrEF patients (with or without T2D), found no significant effect of liraglutide on the change in LVEF with increased arrhythmic events
A Low-Grade Increase of Serum Pancreatic Exocrine Enzyme Levels by Dipeptidyl Peptidase-4 Inhibitor in Patients With Type 2 Diabetes
The individualized approach allows us to maximize the benefits of the medication while keeping side effects to a minimum
It does not directly stimulate insulin release, so the hypoglycemia risk is low